Indications:
Maintenance therapy of schizophrenia in adult patients stabilized by oral aripiprazole.
Hypersensitivity to aripiprazole or any of the components of the drug.
Children and adolescents (up to 18 years) (efficacy and safety of use have not been established).
Breastfeeding period.
Cardiovascular diseases (myocardial infarction, coronary heart disease, heart failure, history of conduction disorders; family history of QT interval prolongation), cerebrovascular diseases or conditions predisposing to the development of arterial hypotension (dehydration, hypovolemia , taking antihypertensive drugs) or hypertension (including progressive or malignant); high risk of developing suicidal behavior and/or ideas: history of convulsive conditions or conditions in which the development of convulsions is likely; simultaneous use with inhibitors and inducers of the CYP3A4 isoenzyme, elderly age (> 65 years), pregnancy.
